statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today provided an update on recent business development...

Nectin Therapeutics Licenses Novel Antibodies to Immunome

Nectin Therapeutics Licenses Novel Antibodies to Immunome Nectin Therapeutics Licenses Novel Antibodies to Immunome PR Newswire JERUSALEM, July 25, 2024 Exclusive worldwide license agreement for...

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief...

Evaluating Immunome: Insights From 4 Financial Analysts

Latest Ratings for IMNM
 DateFirmActionFromTo Oct 2021Cantor FitzgeraldInitiates Coverage OnOverweight Oct 2020Chardan CapitalInitiates Coverage OnBuy
 View More Analyst Ratings for IMNM...

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies...

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial...

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the first quarter ended...

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief...

Immunome Appoints Kinney Horn as Chief Business Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief...

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to...

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Volume	705,040.00
52-Wk High	$30.96
52-Wk Low	$6.13

IMNM Immunome Inc

About

Feed

News

Sentiment

Earnings

Fundamentals